Navigation Links
York U researchers uncovering how ovarian cancer resists chemotherapy
Date:3/2/2011

TORONTO, March 2, 2011 York University researchers have zeroed in on a genetic process that may allow ovarian cancer to resist chemotherapy.

Researchers in the university's Faculty of Science & Engineering studied a tiny strand of our genetic makeup known as a MicroRNA, involved in the regulation of gene expression. Cancer occurs when gene regulation goes haywire.

"Ovarian cancer is a very deadly disease because it's hard to detect," says biology professor Chun Peng, who co-authored the study. By the time it's diagnosed, usually it is in its late stages. And by that point there's really no way to treat the disease. Even when the disease is discovered in its early stages, chemotherapy doesn't always work," she says.

Peng was among a team of researchers that discovered a receptor, ALK7, that induces cell-death in epithelial ovarian cancer cells. They have now discerned that microRNA 376c targets this crucial receptor, inhibiting its expression and allowing ovarian cancer cells to thrive.

"Our evidence suggests that microRNA 376c is crucial to determining how a patient will respond to a chemotherapeutic agent," says Peng. "It allows cancer cells to survive by targeting the very process that kills them off," she says.

In examining tumours taken from patients who were non-responsive to chemotherapy, researchers found a higher expression of microRNA 376c and a much lower expression of ALK7.

Peng believes that this research is a step towards being able to make chemotherapy drugs more effective in the treatment of the disease.

"Further study is needed, but ultimately if we can introduce anti-microRNAs that would lower the level of those microRNAs that make cancer cells resistant to chemotherapeutic drugs, we will be able to make chemotherapy more effective against ovarian cancer," Peng says.

She urges women to educate themselves about the risk factors and symptoms of the disease. For more information, visit http://www.ovariancanada.org .

Peng is a world expert in the area of ovarian cancer and the molecular basis of complications in pregnancy. Her research on chemo-resistance has also contributed to knowledge and prediction of pre-eclampsia, a pregnancy disorder that is a leading cause of maternal and perinatal complications and death.

The article, "MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance," was published in the Journal of Cell Science.


'/>"/>

Contact: Melissa Hughes
mehughes@yorku.ca
416-736-2100 x22097
York University
Source:Eurekalert

Related biology news :

1. Researchers predict age of T cells to improve cancer treatment
2. Researchers looking at a rare disease make breakthrough that could benefit everyone
3. Researchers develop curious snapshot of powerful retinal pigment and its partners
4. 20 researchers selected as 2011 Leopold Leadership Fellows
5. Researchers from Hebrew U., US discover how mercury gets into fish we eat
6. Canadian researchers first worldwide to generate pluripotent stem cells from horses
7. Researchers have found how brain cells control their movement to form the cerebral cortex
8. Cleveland Clinic researchers honored for contributions to science and technology
9. UT researchers crack code to harmful brown tides
10. Iowa State, Ames Lab researchers describe the pump that bacteria use to resist drugs
11. Researchers achieve a full film frame of a family of proteins essential for cell function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... , ... Global Stem Cells Group CEO Benito Novas announced that ... GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in ... hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM Professor ...
(Date:4/26/2016)... , ... April 26, 2016 , ... ... announced that Ardy Arianpour has joined the company as Chief Business Officer. Arianpour, ... bringing innovative genomic technologies to market, was most recently Chief Commercial Officer of ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., ... A round of financing. Healthy investor interest drove significant oversubscription of the original ... biologics, known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and ...
(Date:4/26/2016)... 26, 2016 genae, a Contract ... industries, announced today the appointment of Prof. Dr. Jörn ... Balzer,s responsibilities will include all clinical, safety and risk ... feel privileged and honored with the acceptance of Prof. ... , CEO at genae. "Prof. Balzer,s impressive and extensive ...
Breaking Biology Technology: